18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 485-492

  Soundararajan, Anuradha ^a   Abraham, Jinu ^b   Nelon, Laura D ^a   Prajapati, Suresh I ^a   Zarzabal, Lee Ann ^a   Michalek, Joel E ^a   McHardy, Stanton F ^c   Hawkins, Douglas S ^d   Malempati, Suman ^b   Keller, Charles ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c SOUTHWEST RESEARCH INSTITUTE   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Efficacy; FDG; Imaging; MicroPET; Picropodophyllin; Rhabdomyosarcoma

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUORODEOXYGLUCOSE F 18; PICROPODOPHYLLIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PODOPHYLLOTOXIN; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYONAL RHABDOMYOSARCOMA; GENETIC ENGINEERING; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SPINDLE CELL; SPINDLE CELL SARCOMA; TUMOR VOLUME; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; METHODOLOGY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; MICE; PODOPHYLLOTOXIN; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA;

EID: 84863879676     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24075     Document Type: Article

References (45)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
2. Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 1999; 26: 275-285.
3. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21: 78-84.
4. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002; 1: 97-104.
5. Blandford MC, Barr FG, Lynch JC, et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the Children's Oncology Group. Pediatr Blood Cancer 2006; 46: 329-338.
6. Baselga J, Arribas J. Treating cancer's kinase 'addiction.' Nat Med 2004; 10: 786-787.
7. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010; 36: 318-327.
8. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3: 685-694.
9. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008; 27: 6550-6560.
10. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6: 1-12.
11. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008; 20: 419-427.
12. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337.
13. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009; 14: 83-91.
14. Abraham J, Prajapati SI, Nishijo K, et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther 2011; 10: 697-707.
15. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-IGF-1R monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6304-6312.
16. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64: 236-242.
17. Vasilcanu D, Girnita A, Girnita L, et al. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004; 23: 7854-7862.
18. Ekman S, Frodin JE, Harmenberg J, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: Experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011; 50: 441-447.
19. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: Form and function. Radiology 2007; 242: 360-385.
20. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.
21. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005; 103: 339-348.
22. Cullinane C, Dorow DS, Kansara M, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005; 65: 9633-9636.
23. Cullinane C, Natoli A, Hui Y, et al. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther 2010; 9: 1461-1468.
24. Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: Report of a retrospective case study. Clin Nucl Med 2006; 31: 394-397.
25. Nishijo K, Chen QR, Zhang L, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009; 69: 2902-2911.
26. Rubin BP, Nishijo K, Chen HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011; 19: 177-191.
27. Keller C, Arenkiel BR, Coffin CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18: 2614-2626.
28. Keller C, Hansen MS, Coffin CM, et al. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: Implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004; 18: 2608-2613.
29. McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005; 184: 1293-1304.
30. Baum SH, Fruhwald M, Rahbar K, et al. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 52: 1535-1540.
31. Ekman S, Frodin JE, Harmenberg J, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: Experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 50: 441-447.
32. Ohshima-Hosoyama S, Davare MA, Hosoyama T, et al. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. J Neurooncol 2011; 105: 475-483.
33. Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107: 669-678.
34. Yin S, Girnita A, Stromberg T, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 12: 19-27.
35. Vasilcanu R, Vasilcanu D, Rosengren L, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008; 27: 1629-1638.
36. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288.
37. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56: 595-603.
38. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-688.
39. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68: 8039-8048.
40. Tseng JR, Kang KW, Dandekar M, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 2008; 49: 129-134.
41. Wei LH, Su H, Hildebrandt IJ, et al. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008; 14: 3416-3426.
42. Kobayashi M, Okamoto K, Nakatani H, et al. Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: Report of a case. Surg Today 2006; 36: 727-732.
43. Hong X, Choi H, Loyer EM, et al. Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006; 26: 481-495.
44. Klem ML, Grewal RK, Wexler LH, et al. PET for staging in rhabdomyosarcoma: An evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007; 29: 9-14.
45. La TH, Wolden SL, Rodeberg DA, et al. Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011; 80: 1151-1157.